U.S. FDA Grants Reunion Neuroscience’s Luvesilocin (RE104) Breakthrough Therapy Designation Status February 24, 2026 anxiety ONLY AVAILABLE IN PAID PLANS. Originally reported by hastingstribune. Read more Source: https://www.hastingstribune.com/ap/business/u-s-fda-grants-reunion-neuroscience-s-luvesilocin-re104-breakthrough-therapy-designation-status/article_5b114c3c-802f-52d2-a194-d78b06cfa09e.html
